Biodexa Pharmaceuticals (NASDAQ:BDRX – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.
Insider & Institutional Ownership
17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Biodexa Pharmaceuticals and Cadrenal Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biodexa Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Cadrenal Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Earnings & Valuation
This table compares Biodexa Pharmaceuticals and Cadrenal Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biodexa Pharmaceuticals | $470,000.00 | 4.80 | -$7.32 million | N/A | N/A |
| Cadrenal Therapeutics | N/A | N/A | -$10.65 million | ($8.01) | -0.89 |
Biodexa Pharmaceuticals has higher revenue and earnings than Cadrenal Therapeutics.
Profitability
This table compares Biodexa Pharmaceuticals and Cadrenal Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biodexa Pharmaceuticals | N/A | N/A | N/A |
| Cadrenal Therapeutics | N/A | -279.50% | -204.46% |
Risk & Volatility
Biodexa Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Receive News & Ratings for Biodexa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodexa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
